Treatment of prostate carcinoma
AssigneePellficure Pharmaceuticals, Inc.
InventorPer Borgström
Life of this patent
Estimating the term…
Abstract
Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
Claims12
A method of inhibiting or delaying the growth of prostate cancer, comprising administering to a human having prostate cancer a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt of Formula (I):
- wherein:
- R1 is methyl;
- R2 is hydrogen;
- R3 is —OH;
- R4 is hydrogen;
- R5 is hydrogen;
- R6 is hydrogen;
- and
- wherein the compound of Formula (I) is administered to the human in combination with, subsequent to, or concomitantly with, an androgen deprivation therapy that reduces production of dihydrotestosterone (DHT), androsterone, androstenediol, androstenedione, dehydroepiandrosterone (DHEA), or dehydroepiandrosterone sulfate (DHEA-S);
- and wherein the growth of prostate cancer is inhibited or delayed.
Dependencies are inferred from the claim text.